JP2017525364A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017525364A5 JP2017525364A5 JP2017509626A JP2017509626A JP2017525364A5 JP 2017525364 A5 JP2017525364 A5 JP 2017525364A5 JP 2017509626 A JP2017509626 A JP 2017509626A JP 2017509626 A JP2017509626 A JP 2017509626A JP 2017525364 A5 JP2017525364 A5 JP 2017525364A5
- Authority
- JP
- Japan
- Prior art keywords
- mesenchymal stem
- stem cell
- genetically modified
- promoter
- modified mesenchymal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims 38
- 206010028980 Neoplasm Diseases 0.000 claims 16
- 102000004127 Cytokines Human genes 0.000 claims 15
- 108090000695 Cytokines Proteins 0.000 claims 15
- 238000011398 antitumor immunotherapy Methods 0.000 claims 14
- 230000028993 immune response Effects 0.000 claims 14
- 230000004936 stimulating effect Effects 0.000 claims 14
- 108010012236 Chemokines Proteins 0.000 claims 9
- 102000019034 Chemokines Human genes 0.000 claims 9
- 210000002865 immune cell Anatomy 0.000 claims 9
- 108010002586 Interleukin-7 Proteins 0.000 claims 6
- 239000000427 antigen Substances 0.000 claims 6
- 102000036639 antigens Human genes 0.000 claims 6
- 108091007433 antigens Proteins 0.000 claims 6
- 239000003623 enhancer Substances 0.000 claims 6
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 5
- 108010065805 Interleukin-12 Proteins 0.000 claims 5
- 102100030704 Interleukin-21 Human genes 0.000 claims 5
- 210000001744 T-lymphocyte Anatomy 0.000 claims 5
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 5
- 108010074108 interleukin-21 Proteins 0.000 claims 5
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- 102000039446 nucleic acids Human genes 0.000 claims 5
- 108020004707 nucleic acids Proteins 0.000 claims 5
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 4
- 108091007741 Chimeric antigen receptor T cells Proteins 0.000 claims 4
- 108090000172 Interleukin-15 Proteins 0.000 claims 4
- 108010002350 Interleukin-2 Proteins 0.000 claims 4
- 102100036842 C-C motif chemokine 19 Human genes 0.000 claims 2
- 102100036850 C-C motif chemokine 23 Human genes 0.000 claims 2
- -1 CCL22 Proteins 0.000 claims 2
- 239000012275 CTLA-4 inhibitor Substances 0.000 claims 2
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 2
- 101000713106 Homo sapiens C-C motif chemokine 19 Proteins 0.000 claims 2
- 101000713081 Homo sapiens C-C motif chemokine 23 Proteins 0.000 claims 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 2
- 239000012270 PD-1 inhibitor Substances 0.000 claims 2
- 239000012668 PD-1-inhibitor Substances 0.000 claims 2
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 claims 2
- 101710088580 Stromal cell-derived factor 1 Proteins 0.000 claims 2
- 230000006052 T cell proliferation Effects 0.000 claims 2
- 108091008874 T cell receptors Proteins 0.000 claims 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 230000035605 chemotaxis Effects 0.000 claims 2
- 230000004069 differentiation Effects 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 230000003308 immunostimulating effect Effects 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- 239000003446 ligand Substances 0.000 claims 2
- 210000002540 macrophage Anatomy 0.000 claims 2
- 239000000463 material Substances 0.000 claims 2
- 238000011133 mesenchymal stem cell therapy Methods 0.000 claims 2
- 210000001616 monocyte Anatomy 0.000 claims 2
- 229940121655 pd-1 inhibitor Drugs 0.000 claims 2
- 230000035899 viability Effects 0.000 claims 2
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 1
- 102100032367 C-C motif chemokine 5 Human genes 0.000 claims 1
- 101710163595 Chaperone protein DnaK Proteins 0.000 claims 1
- 108010055166 Chemokine CCL5 Proteins 0.000 claims 1
- 102000006573 Chemokine CXCL12 Human genes 0.000 claims 1
- 108010008951 Chemokine CXCL12 Proteins 0.000 claims 1
- 101100481408 Danio rerio tie2 gene Proteins 0.000 claims 1
- 101710178376 Heat shock 70 kDa protein Proteins 0.000 claims 1
- 101710152018 Heat shock cognate 70 kDa protein Proteins 0.000 claims 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 1
- 101100481410 Mus musculus Tek gene Proteins 0.000 claims 1
- 239000012271 PD-L1 inhibitor Substances 0.000 claims 1
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 1
- 230000024245 cell differentiation Effects 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 229940121656 pd-l1 inhibitor Drugs 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
- 210000002536 stromal cell Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14181283.4 | 2014-08-18 | ||
| EP14181283 | 2014-08-18 | ||
| PCT/EP2015/068942 WO2016026854A2 (en) | 2014-08-18 | 2015-08-18 | Genetically modified mesenchymal stem cells expressing an immune response-stimulating cytokine to attract and/or activate immune cells |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017525364A JP2017525364A (ja) | 2017-09-07 |
| JP2017525364A5 true JP2017525364A5 (enExample) | 2018-09-20 |
| JP6712993B2 JP6712993B2 (ja) | 2020-06-24 |
Family
ID=51352460
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017509626A Active JP6712993B2 (ja) | 2014-08-18 | 2015-08-18 | 免疫細胞を惹起及び／又は活性化するための免疫応答刺激性サイトカインを発現する遺伝子改変型間葉系幹細胞 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20170239297A1 (enExample) |
| EP (2) | EP3182984B1 (enExample) |
| JP (1) | JP6712993B2 (enExample) |
| CN (1) | CN106659742B (enExample) |
| AU (1) | AU2015306231B2 (enExample) |
| CA (1) | CA2956987C (enExample) |
| IL (1) | IL250388B (enExample) |
| WO (1) | WO2016026854A2 (enExample) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201202319D0 (en) | 2012-02-10 | 2012-03-28 | Orbsen Therapeutics Ltd | Stromal stem cells |
| WO2015124297A1 (en) * | 2014-02-19 | 2015-08-27 | Merck Patent Gmbh | Cancer-targeted il-12 immunotherapy |
| AU2017242899A1 (en) * | 2016-04-01 | 2018-07-05 | Apceth Gmbh & Co. Kg | Mesenchymal stem cells to enhance anti-tumor activity of immunotherapy |
| US11529393B2 (en) | 2016-10-10 | 2022-12-20 | The Board Of Trustees Of The Leland Stanford Junior University | Mesenchymal stem cells expressing anti-inflammatory cytokines and methods of use |
| CN108148862B (zh) | 2016-12-05 | 2019-03-08 | 上海优卡迪生物医药科技有限公司 | 一种封闭pdl1的用于抑制免疫逃脱的car-t转基因载体及其构建方法和应用 |
| WO2018170390A1 (en) * | 2017-03-17 | 2018-09-20 | Senti Biosciences, Inc. | Immunomodulating cell circuits |
| MX2019011847A (es) * | 2017-04-07 | 2019-11-21 | Cynata Therapeutics Ltd | Metodo para tratar un efecto secundario de la terapia de celulas t con receptor de antigeno quimerico (car). |
| EP4317422A3 (en) | 2017-04-13 | 2024-05-01 | Senti Biosciences, Inc. | Combinatorial cancer immunotherapy |
| CN107184602B (zh) * | 2017-06-01 | 2020-06-30 | 刘未斌 | 一种治疗肿瘤的药物组合 |
| CN107184603B (zh) * | 2017-06-01 | 2020-06-30 | 刘未斌 | 一种治疗肿瘤的药物组合 |
| JP2020523400A (ja) * | 2017-06-16 | 2020-08-06 | サイナータ セラピューティクス リミテッド | 免疫療法の副作用を治療するための方法 |
| WO2019067491A1 (en) * | 2017-09-29 | 2019-04-04 | Oncocyclist, Inc. | COMPOSITION AND METHOD FOR TREATING CELL PROLIFERATION |
| CN111386123A (zh) * | 2017-11-22 | 2020-07-07 | 布里格姆及妇女医院股份有限公司 | Msc表达的免疫调节剂与car-t结合用于癌症治疗 |
| NZ749727A (en) | 2018-01-05 | 2020-07-31 | Gnt Biotech & Medicals Corp | A pharmaceutical combination and method for regulation of tumor microenvironment and immunotherapy |
| JP2021510510A (ja) * | 2018-01-12 | 2021-04-30 | ラトガース，ザ ステート ユニバーシティ オブ ニュー ジャージー | 細胞再プログラム化療法 |
| SG11202005036RA (en) | 2018-01-25 | 2020-06-29 | I Mab Biopharma Us Ltd | Anti-pd-l1 antibody and il-7 fusions |
| WO2019151759A1 (ko) * | 2018-02-02 | 2019-08-08 | 주식회사 에스엘백시젠 | 신규 백신 면역보조제 |
| US11458171B2 (en) * | 2018-03-21 | 2022-10-04 | China Medical University | Engineering stem cells for cancer therapy |
| CN108864288A (zh) * | 2018-04-26 | 2018-11-23 | 上海怡豪生物科技有限公司 | 乳腺癌的双靶点car-t治疗载体及其构建方法和应用 |
| CN110527696A (zh) * | 2018-06-13 | 2019-12-03 | 中山大学 | 一种IFNβ和FerritinH基因联合修饰的骨髓间充质干细胞及其制备方法和应用 |
| CN108815188A (zh) * | 2018-07-06 | 2018-11-16 | 浙江生创精准医疗科技有限公司 | 包含间充质干细胞制剂与免疫检查点抑制剂的肿瘤治疗组合物、试剂盒及其用途 |
| CN112384231A (zh) * | 2018-08-26 | 2021-02-19 | 奥伊斯细胞生物技术公司 | 用于治疗胶质母细胞瘤的方法 |
| CN112771167B (zh) * | 2018-09-20 | 2025-09-26 | 克莱格医学有限公司 | 表达有趋化因子的细胞及用途 |
| EP3864142A4 (en) * | 2018-10-12 | 2023-07-19 | iCell Gene Therapeutics LLC | CHEMERA ANTIGEN RECEPTORS (CARs), COMPOSITIONS AND METHODS OF USE THEREOF |
| US11419898B2 (en) | 2018-10-17 | 2022-08-23 | Senti Biosciences, Inc. | Combinatorial cancer immunotherapy |
| CN113164518B (zh) * | 2018-10-17 | 2025-06-24 | 森迪生物科学公司 | 组合癌症免疫疗法 |
| CN109593725A (zh) * | 2018-12-25 | 2019-04-09 | 河北生命原点生物科技有限公司 | 一种重组间充质干细胞及其应用 |
| BR112021015791A2 (pt) * | 2019-02-14 | 2021-10-05 | Research Institute At Nationwide Children's Hospital | Uso de partículas de membrana plasmática, lipossomas e exossomas para testar a potência de células imunes |
| CN109762820B (zh) * | 2019-02-18 | 2020-07-28 | 河北佑仁生物科技有限公司 | 一种骨髓间充质干细胞特异性启动元件在干细胞中的应用 |
| US20220143099A1 (en) * | 2019-04-02 | 2022-05-12 | The General Hospital Corporation | Methods to enhance t cell regeneration |
| CN115851605A (zh) * | 2019-04-18 | 2023-03-28 | 上海交通大学 | 间充质干细胞靶向运输趋化因子和细胞因子的免疫疗法 |
| CN111139222B (zh) * | 2019-05-30 | 2020-12-29 | 北京双因生物科技有限公司 | 一种重组间充质干细胞及其制备方法和用途 |
| WO2021038289A1 (en) * | 2019-08-23 | 2021-03-04 | Orbsen Therapeutics Limited | Compositions for monocyte and macrophage polarization and methods of use |
| US20230105923A1 (en) * | 2020-03-26 | 2023-04-06 | Agency For Science, Technology And Research | A method and system for introducing one or more exogenous substances into an immune cell |
| MX2022014766A (es) * | 2020-05-27 | 2023-02-22 | Univ Zuerich | Vectores virales que expresan proteinas terapeuticas especificamente en celulas mieloides y microglia. |
| JP7758370B2 (ja) * | 2020-07-16 | 2025-10-22 | チャンジェン セラピューティクス （シャンハイ） カンパニー リミテッド | 間葉系幹細胞によるケモカインおよびサイトカイン送達を標的とする免疫療法 |
| EP4229182A1 (en) * | 2020-10-16 | 2023-08-23 | Fundació Centre de Regulació Genòmica | Therapy for degenerative disease and tissue damage |
| CN114507643A (zh) * | 2020-10-29 | 2022-05-17 | 未来智人再生医学研究院(广州)有限公司 | 一种表达il-2的多能干细胞衍生物及应用 |
| CN114426953A (zh) * | 2020-10-29 | 2022-05-03 | 未来智人再生医学研究院(广州)有限公司 | 一种表达il-12的多能干细胞衍生物及应用 |
| CN114717232A (zh) * | 2020-12-22 | 2022-07-08 | 未来智人再生医学研究院(广州)有限公司 | 表达irf-1靶向抑制因子的多能干细胞及其衍生物与应用 |
| WO2023274355A1 (zh) * | 2021-07-02 | 2023-01-05 | 上海交通大学 | 改造的间充质干细胞和免疫效应细胞联合治疗肿瘤 |
| WO2023076670A1 (en) * | 2021-11-01 | 2023-05-04 | MAM Holdings of West Florida, L.L.C. | Mesenchymal stem cells for the prevention and targeted treatment of cancer and other disorders |
| CN114480413B (zh) * | 2022-01-14 | 2022-11-04 | 北京贝来生物科技有限公司 | 一种活化肿瘤免疫应答的基因修饰干细胞制备方法 |
| CN115463155B (zh) * | 2022-11-01 | 2023-05-23 | 卡瑞济(北京)生命科技有限公司 | 间充质干细胞的用途 |
| CN117503952B (zh) * | 2022-11-24 | 2025-09-16 | 中国药科大学 | 一种基于血小板的免疫激活系统及其制备方法和应用 |
| WO2024137869A2 (en) * | 2022-12-20 | 2024-06-27 | City Of Hope | Stem cells for delivery of oncolytic viruses |
| US20250333700A1 (en) * | 2024-02-28 | 2025-10-30 | Gene Solutions Joint Stock Company | Modified k562 feeder cell line expressing factors that enhance the activation and proliferation of natural killer cells and a method for its production |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005531507A (ja) | 2002-03-02 | 2005-10-20 | ザ ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | ストローマ細胞前駆体による抗癌物質の局所的な産生および／または送達方法 |
| CN1842339A (zh) * | 2003-06-27 | 2006-10-04 | 株式会社雷诺再生医学研究所 | 含有间叶细胞作为有效成分、治疗脑神经疾病的体内给药治疗剂 |
| CA2535034A1 (en) * | 2003-06-27 | 2005-01-27 | Renomedix Institute Inc | Internallly administered therapeutic agents for diseases in central and peripheral nervous system comprising mesenchymal cells as an active ingredient |
| US20050002904A1 (en) | 2003-07-03 | 2005-01-06 | Wary Kishore K. | Uses of vascular endothelial growth factor and type I collagen inducible protein (VCIP) |
| JP5089389B2 (ja) * | 2004-09-10 | 2012-12-05 | コグネート セラピューティクス，インコーポレーテッド | 移植における免疫応答の予防および治療のための肝臓間質細胞 |
| EP1757703A3 (en) | 2005-08-24 | 2007-12-05 | Medizinische Hochschule Hannover | Self-inactivating retroviral vector |
| CN103263439B (zh) * | 2007-05-24 | 2015-04-22 | 埃普塞斯有限责任两合公司 | Cd34干细胞相关方法和组合物 |
| EP2019134A1 (en) | 2007-07-26 | 2009-01-28 | Vision 7 GmbH | Gene therapy of chronic granulomatous disease |
| WO2011087637A1 (en) * | 2009-12-08 | 2011-07-21 | The Board Of Trustees Of The University Of Illinois | Stem cell immune modulation methods of use and apparatus |
| CA2758120C (en) | 2009-04-13 | 2014-08-19 | Apceth Gmbh & Co. Kg | Engineered mesenchymal stem cells and method of using same to treat tumors |
| CN101974485A (zh) * | 2010-11-12 | 2011-02-16 | 苏州大学 | 具有最佳迁移能力的间充质干细胞的制备方法及其应用 |
| US9101597B2 (en) | 2013-03-14 | 2015-08-11 | The Administration Of The Tulane Educational Fund | Immunoprotective primary mesenchymal stem cells and methods |
| EP3047275B1 (en) * | 2013-09-06 | 2020-11-18 | Consejo Nacional De Investigaciones Cientificas Y Tecnicas | Compositions and methods for increasing mesenchymal stromal cell migration to tumors |
| EP4303229A3 (en) * | 2014-01-21 | 2024-04-17 | Novartis AG | Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules |
| WO2016146819A1 (en) * | 2015-03-18 | 2016-09-22 | Apceth Gmbh & Co. Kg | Hypoxia-induced expression of therapeutic proteins in mesenchymal stem cells |
-
2015
- 2015-08-18 EP EP15759667.7A patent/EP3182984B1/en active Active
- 2015-08-18 AU AU2015306231A patent/AU2015306231B2/en active Active
- 2015-08-18 WO PCT/EP2015/068942 patent/WO2016026854A2/en not_active Ceased
- 2015-08-18 US US15/504,554 patent/US20170239297A1/en not_active Abandoned
- 2015-08-18 EP EP19205297.5A patent/EP3656387A3/en not_active Withdrawn
- 2015-08-18 JP JP2017509626A patent/JP6712993B2/ja active Active
- 2015-08-18 CA CA2956987A patent/CA2956987C/en active Active
- 2015-08-18 CN CN201580045089.6A patent/CN106659742B/zh active Active
-
2017
- 2017-02-01 IL IL250388A patent/IL250388B/en active IP Right Grant
-
2020
- 2020-01-28 US US16/774,495 patent/US11464806B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017525364A5 (enExample) | ||
| Lim et al. | Type I interferons induced by radiation therapy mediate recruitment and effector function of CD8+ T cells | |
| Cerboni et al. | Cytokine‐regulated Th17 plasticity in human health and diseases | |
| Brempelis et al. | Genetically engineered macrophages persist in solid tumors and locally deliver therapeutic proteins to activate immune responses | |
| Dobrzanski | Expanding roles for CD4 T cells and their subpopulations in tumor immunity and therapy | |
| Lee et al. | The dual nature of type I and type II interferons | |
| Alpdogan et al. | IL-7 and IL-15: therapeutic cytokines for immunodeficiency | |
| Setrerrahmane et al. | Tumor-related interleukins: old validated targets for new anti-cancer drug development | |
| CN110913871B (zh) | 生成哺乳动物t细胞活化诱导型合成启动子(syn+pro)以改善t细胞疗法 | |
| Christopherson et al. | Chemokine regulation of normal and pathologic immune responses | |
| Reichman et al. | Emerging roles for eosinophils in the tumor microenvironment | |
| Mitchell et al. | Distinct roles for IL-2 and IL-15 in the differentiation and survival of CD8+ effector and memory T cells | |
| CN106659742B (zh) | 表达免疫应答刺激细胞因子以吸引和/或激活免疫细胞的基因修饰间充质干细胞 | |
| Cox et al. | Cytokines and the inception of CD8 T cell responses | |
| Xie et al. | The role of CD4+ T cells in tumor and chronic viral immune responses | |
| Darcy et al. | Manipulating immune cells for adoptive immunotherapy of cancer | |
| Hervas-Stubbs et al. | CD8 T cell priming in the presence of IFN-α renders CTLs with improved responsiveness to homeostatic cytokines and recall antigens: important traits for adoptive T cell therapy | |
| HK1257460A1 (zh) | 用於免疫疗法的巨噬细胞的遗传工程 | |
| Ogata et al. | Plasmacytoid dendritic cells have a cytokine-producing capacity to enhance ICOS ligand-mediated IL-10 production during T-cell priming | |
| JP2018526450A5 (enExample) | ||
| JP2018528774A5 (enExample) | ||
| JP2018514199A5 (enExample) | ||
| JP2012504959A5 (enExample) | ||
| JP2019509715A5 (enExample) | ||
| JP2019536457A5 (enExample) |